Hope For Price Flexibility After India Pretomanid Go-Ahead
Mylan gets approval in India for pretomanid as part of a combination regimen with bedaquiline and linezolid, providing new hope to patients with drug-resistant tuberculosis. Volume changes may provide opportunities to tweak prices.
You may also be interested in...
Viatris, MedAccess and TB Alliance deal to lower the price of pretomanid, a key drug used as part of a shorter all-oral drug regime for multidrug-resistant TB, but country-level prioritization and uptake of the treatment option will be pivotal to widen access sharply.
Lupin and non-profit organization TB Alliance have entered into a partnership for a new therapy for highly drug-resistant tuberculosis, pretomanid, to be distributed in 140 countries and territories.
TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.